lipolysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
==== China ==== In China a number of think tanks are sponsored by governmental agencies such as Development Research Center of the State Council, but still retain sufficient non-official status to be able to propose and debate ideas more freely. In January 2012, the first non-official think tank in mainland China, South Non-Governmental Think-Tank, was established in the Guangdong province. In 2009 the China Center for International Economic Exchanges was founded.
The Colombian Army's assault on the FARC's Casa Verde sanctuary at La Uribe, Meta, followed by a FARC offensive that sought to undermine the deliberations of the Constitutional Assembly, began to highlight a significant break in the uneven negotiations carried over from the previous decade. Nevertheless, both parties never completely broke off some amount of political contacts for long, as some peace feelers continued to exist, leading to short rounds of conversations in both Caracas, Venezuela (1991) and Tlaxcala, Mexico (1992). Despite the signing of several documents, no concrete results were achieved when the talks ended.
Puffballs are a type of fungus featuring a ball-shaped fruiting body that, when mature, bursts on contact or impact, releasing a cloud of dust-like spores into the surrounding area. Puffballs belong to the division Basidiomycota and encompass several genera, including Calvatia, Calbovista and Lycoperdon. The puffballs were previously treated as a taxonomic group called the Gasteromycetes or Gasteromycetidae, but they are now known to be a polyphyletic assemblage. The distinguishing feature of all puffballs is that they do not have an open cap with spore-bearing gills. Instead, spores are produced internally, in a spheroidal fruit body called a gasterothecium (gasteroid 'stomach-like' basidiocarp). As the spores mature, they form a mass called a gleba in the centre of the fruitbody that is often of a distinctive color and texture. The basidiocarp remains closed until after the spores have been released from the basidia. Eventually, it develops an aperture, or dries, becomes brittle, and splits, and the spores escape. The spores of puffballs are statismospores rather than ballistospores, meaning they are not forcibly extruded from the basidium. Puffballs and similar forms are thought to have evolved convergently (that is, in numerous independent events) from Hymenomycetes by gasteromycetation, through secotioid stages. Thus, 'Gasteromycetes' and 'Gasteromycetidae' are now considered to be descriptive, morphological terms (more properly gasteroid or gasteromycetes, to avoid taxonomic implications) but not valid cladistic terms.
Adrenodoxin reductase: This enzyme is present ubiquitously in most organisms. It transfers two electrons from NADPH to FAD. In vertebrates, it serves as the first enzyme in the chain of mitochondrial P450 systems that synthesize steroid hormones.
=== Baháʼí Faith === While there are no dietary restrictions in the Baháʼí Faith, `Abdu'l-Bahá, the son of the religion's founder, noted that a vegetarian diet consisting of fruits and grains was desirable, except for people with a weak constitution or those that are sick. He stated that there are no requirements that Baháʼís become vegetarian, but that a future society should gradually become vegetarian. `Abdu'l-Bahá also stated that killing animals was contrary to compassion. While Shoghi Effendi, the head of the Bahá'í Faith in the first half of the 20th century, stated that a purely vegetarian diet would be preferable since it avoided killing animals, both he and the Universal House of Justice, the governing body of the Baháʼís have stated that these teachings do not constitute a Baháʼí practice and that Baháʼís can choose to eat whatever they wish but should be respectful of others' beliefs.
Sources: en.wikipedia.org
food and dietary supplement labeling purposes, the amount in a serving is expressed as a "percent of daily value" (%DV). For vitamin B12 labeling purposes, 100% of the daily value was 6.0 μg, but on 27 May 2016, it was revised downward to 2.4 μg (see Reference Daily Intake). Compliance with the updated labeling regulations was required by 1 January 2020 for manufacturers with US$10 million or more in annual food sales, and by 1 January 2021 for manufacturers with lower volume food sales.
Aila Inkeri Keto AO (born 14 March 1943) is an Australian environmentalist. She is the founder and President of the Rainforest Conservation Society in Queensland, Australia, now known as the Australian Rainforest Conservation Society. In 2005, Keto was a recipient of the Queensland Greats Awards. Born in Tully, Queensland, Australia, to parents of Finnish origin, Dr Keto originally studied biochemistry and worked at the University of Queensland. In 1992, Keto received the IUCN Fred M. Packard Award in recognition of "outstanding service to protected and conserved areas" and in 1994 she was awarded an Officer of the Order of Australia for “service to conservation, particularly through promoting the protection and management of the wet tropical rainforests of Queensland”. She was nominated as Queenslander of the Year in 2000 and in 2001 she was awarded a Centenary Medal, "for service as an expert on wet tropics and as a leading conservationist and academic". In 2005, Dr Keto was awarded the Volvo Environment Prize for her work which, led to the protection of more than 15,000 square kilometres (5,800 sq mi) of Queensland's rainforest. This is only one of a series of awards that have been given to her for her environmental and conservation work which has resulted in three successful nominations for world heritage status: Wet Tropics, Fraser Island and the Central Eastern Rainforest Reserves of Australia (now Gondwana Rainforests of Australia).
The initial force of 500 armed Huks which was organized into five squadrons had increased to a fully armed guerrilla force of 20,000 men. By 1944, Huk strength numbers at 76 squadrons. After the Cabiao raid by the Japanese, the PKP adopted a "retreat for defense" policy, which broke up squads to smaller groups of three to five men. In areas controlled by Huk guerrillas, the Huks organized an ad-hoc police force to keep the peace and stop looters and thieves. Huks also formed Sandatahang Tanod ng Bayan (Barrio United Defense Corps), which acted as neighborhood governments in support of the Huk forces in the field. These BUDC's were composed of KPMP and AMT members, which organized popular support for Huks, shielded harvest from the Japanese, and attacked Filipino collaborators; in effect, setting up protected zones and safe havens for the Huks. The Hukbalahap also set-up a government, composed of a President, Vice-President, Secretary, Treasurer, and five policemen. The barrio government also had three departments, with a person-in-charge leading it. One department collected intelligence information about the military, another handled communication between different barrios and Huk members, and the third arranged for supplies. The Hukbalahap government also performed civil tasks, such as officiating in weddings, baptisms, funerals, and issued marriage licenses and birth certificates.
== Treatment == There is no known antidote for pennyroyal toxicity. Case studies involving pennyroyal poisonings have reported the use of gastric lavages and administration of emetics or vomiting inducing agents, or absorbents like activated charcoal. As glutathione depletion has been shown to regulate liver toxification, administration of N-acetylcysteine in similar doses as given for acetaminophen toxicity have been given to patients. A study testing pulegone toxicity found inhibitors of cytochrome P450, such as cobaltous chloride or piperonyl butoxide, blocked toxicity. Such testing has not been expanded to humans, however, as the pennyroyal mechanism of toxicity is still not entirely understood.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.